Lack of neuroprotective effect for amiloride, fluoxetine and riluzole in the MS-SMART trial

Takeaway

  • Amiloride, fluoxetine and riluzole show a lack efficacy in people with secondary progressive multiple sclerosis (MS) treated in the MS-SMART trial.

Why this matters

  • Few treatments are currently available that can slow, stop or reverse progressive MS. It remains unclear if directly targeting axonal pathobiologies is an effective therapeutic strategy.

  • Multiarm trials such as MS-SMART offer a way to accelerate treatment discovery by assessing multiple disease-modifying treatments at the same time.

Want to read more?

Log in or sign up to access all Neurodiem content.

Already have an account? Log In

International Medical Press is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by International Medical Press for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, International Medical Press recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of International Medical Press or the sponsor. International Medical Press assumes no liability for any material contained herein.